Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200801 | 0.79 | KDM4E (0.58) | MAPTKDM4EEPHX2LPAR1LPAR3 | |
| SCHEMBL4035675 | 0.77 | MAPT (0.67) | MAPTKDM4ELPAR1LPAR3KMT2A | |
| SCHEMBL1911307 | 0.75 | MAPT (0.53) | MAPTKDM4ELPAR1LPAR3 | |
| SCHEMBL5529169 | 0.73 | MAPT (0.62) | MAPTKDM4ELPAR1LPAR3KMT2A | |
| SCHEMBL4112211 | 0.72 | EPHX2 (0.64) | MAPTEPHX2FAAHKMT2A | |
| SCHEMBL1420825 | 0.72 | EPHX2 (0.68) | EPHX2KMT2A | |
| SCHEMBL5537590 | 0.68 | ATM (0.56) | MAPTKDM4ELPAR1LPAR3KMT2A | |
| SCHEMBL4037272 | 0.68 | MAPT (0.54) | MAPTKDM4ELPAR1LPAR3KMT2A | |
| SCHEMBL5772191 | 0.68 | LPAR1 (0.57) | MAPTKDM4ELPAR1LPAR3KMT2A | |
| SCHEMBL12576957 | 0.67 | FAAH (0.50) | EPHX2FAAHKMT2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960352-B1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | claimed |
| US-8466200-B2 | 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | claimed |
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-05 | — | — | US | claimed |
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | claimed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | claimed |
| EP-1960352-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2008-08-27 | — | — | EP | claimed |
| EP-1801098-A1 | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors | Merck Sante (FR) | 2007-06-27 | — | — | EP | claimed |
| WO-2007068330-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2007-06-21 | — | — | WO | claimed |
| EP-1960352-B1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-8466200-B2 | 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-1960352-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1801098-A1 | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors | Merck Sante (FR) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007068330-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | MAPT 1283/4885KDM4E 3760/4885EPHX2 597/4885 |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | MAPT 1493/4885KDM4E 3961/4885EPHX2 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.